Journal of Schizophrenia Disorders And Therapy

Aims And Scope

The Journal of Schizophrenia Disorders And Therapy (JSDT) is an open access, peer-reviewed journal that aims to provide a platform for researchers to share their knowledge and findings in the field of schizophrenia research and therapy. It serves as a resource for researchers, healthcare professionals, and patients, allowing them to stay up to date with the latest scientific developments in the field.

JSDT is dedicated to understanding the neurobiology, genetics, epidemiology, and treatment of schizophrenia, as well as ways to promote mental health and wellness among people diagnosed with schizophrenia and their families.

The journal seeks to inform and educate readers about the etiology, diagnosis, treatment, and management of schizophrenia and related disorders as well as to promote an interdisciplinary approach to understanding and treating these conditions. The journal also focuses on topics such as neurobiology, neuroimaging, pharmacology, genetics, neurochemistry, neurodevelopmental aspects, and behavioral treatment of schizophrenia and related disorders.

It aims to provide an international forum for the exchange of ideas and research findings concerning the causes, treatment, and prevention of schizophrenia and related mental disorders. 

JSDT embraces diverse topics and provides a platform for advances in schizophrenia research and therapy. The scope of the journal includes the following areas:

Epidemiology and public health impact of schizophrenia
Neurobiology and neuroimaging of schizophrenia
Pharmacology, genetics, and neurochemistry of schizophrenia
Neurodevelopmental aspects of schizophrenia
Clinical descriptions and treatment of schizophrenia
Behavioral therapies for schizophrenia
Impact of schizophrenia on the quality of life
Comorbidity in schizophrenia
Cultural aspects of schizophrenia
Integrated treatment of schizophrenia
Mental health services for schizophrenia patient

Contributions from the following research areas are invited but not limited to the following branches :

• Adolescent-onset schizophrenia
• Animal-assisted therapy
• Antipsychotic medications
• Anxiety disorders
• Attention-deficit/hyperactivity disorder
• Autism spectrum disorder
• Bipolar disorder
• Clozapine
• Cognitive impairment
• Cognitive Science
• Cognitive-behavioral therapy
• Complementary and alternative medicine
• Deep brain stimulation
• Delusions
• Depression
• Dual diagnosis
• Electroconvulsive therapy
• Family therapy
• First-episode psychosis
• First-generation antipsychotics
• Group therapy
• Hallucinations
• Herbal remedies
• Hyperprolactinemia
• Integrated care
• Long-term prognosis
• Major depressive disorder
• Medication management
• Mental Health Illiteracy
• Mental Health Morbidity
• Negative symptoms
• Neurobiology
• Neurodevelopmental disorders
• Neuropsychology
• Obsessive-compulsive disorder
• Occupational therapy
• Paranoid type
• Personality disorders
• Pharmacogenomics
• Positive symptoms
• Post-traumatic stress disorder
• Prolactin
• Psychopharmacology
• Psychosis
• Psychotherapy
• Psychotic disorders
• Recovery-oriented services
• Rehabilitation
• Schizoaffective Disorder
• Schizophrenia
• Second-generation antipsychotics
• Social skills training
• Substance use disorders
• Suicide tendency
• Supportive psychotherapy
• Telepsychiatry
• Transcranial magnetic stimulation
• Virtual reality therapy
• Vocational training
•